| Project/Area Number |
25461894
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UTSUNOMIYA KEITA 関西医科大学, 医学部, 講師 (20193914)
KARIYA SHUJI 関西医科大学, 医学部, 准教授 (40368220)
KOHNO YUMIKO 関西医科大学, 医学部, 助教 (10598957)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 放射性同位元素 / 肝細胞癌 / 肝動脈塞栓術 / RI標識リピオドール |
|---|
| Outline of Final Research Achievements |
Transarterial chemoembolization is essential for unresectable hepatocellular carcinoma. We developed new radioembolization using Y-90 labeled lipiodol. Treatment model was divided into three groups according to the embolic materials, that is, lipiodol group, Y-90 labeled lipiodol group, and no treatment group, and treatment effects were compared among the three groups. The rabbits treated with Y-90 labeled lipiodol got the longest term survival among the three groups. New radioembolization using Y-90 labeled lipiodol is thought to be effective and shown the result of which the additional effect is expected compared with the conventional embolization.
|
